Abstract
Objectives/Methods: Elevated CRP levels predict increased incidence of cardiovascular events and poor outcomes following interventions. There is the suggestion that CRP is also a mediator of vascular injury. Transgenic mice carrying the human CRP gene (CRPtg) are predisposed to arterial thrombosis post-injury. We examined whether CRP similarly modulates the proliferative and hyperplastic phases of vascular repair in CRPtg when thrombosis is controlled with daily aspirin and heparin at the time of trans-femoral arterial wire-injury. Results: Complete thrombotic arterial occlusion at 28 days was comparable for wild-type and CRPtg mice (14 and 19%, respectively). Neointimal area at 28d was 2.5 fold lower in CRPtg (4190 ± 3134 μm2, n = 12) compared to wild-types (10,157 ± 8890 μm2, n = 11, p < 0.05). Likewise, neointimal/media area ratio was 1.10 ± 0.87 in wild-types and 0.45 ± 0.24 in CRPtg (p < 0.05). Seven days post-injury, cellular proliferation and apoptotic cell number in the intima were both less pronounced in CRPtg than wild-type. No differences were seen in leukocyte infiltration or endothelial coverage. CRPtg mice had significantly reduced p38 MAPK signaling pathway activation following injury. Conclusions: The pro-thrombotic phenotype of CRPtg mice was suppressed by aspirin/heparin, revealing CRP's influence on neointimal growth after trans-femoral arterial wire-injury. Signaling pathway activation, cellular proliferation, and neointimal formation were all reduced in CRPtg following vascular injury. Increasingly we are aware of CRP multipotent effects. Once considered only a risk factor, and recently a harmful agent, CRP is a far more complex regulator of vascular biology.
Original language | English |
---|---|
Pages (from-to) | 85-91 |
Number of pages | 7 |
Journal | Atherosclerosis |
Volume | 201 |
Issue number | 1 |
DOIs | |
State | Published - Nov 2008 |
Externally published | Yes |
Funding
This work was supported in part by the Israel Sciences Foundation Grant (ISF #655/05) to HDD, and NIH grant (HL40309) to ERE.
Funders | Funder number |
---|---|
Israel Sciences Foundation | ISF #655/05 |
National Institutes of Health | HL40309 |
National Heart, Lung, and Blood Institute | R37HL057506 |
Keywords
- Angioplasty
- C-reactive protein
- Neointima
- p38 MAPK